This is the authors' abstract. We don't add key points for this paper.
by Gu, Y., et al. (2019). Frontiers in immunology. 10 Further, the assessment scale of disease severity in research needs more discussion. The authors have used the Glasgow Outcome Scale (GOS) to evaluate factors that may be associated with disease prognosis. [1] The GOS was designed in 1974 [4] to predict the outcome after brain injury-like traumas. [5][6][7][8] However, some researchers have indicated that GOS cannot detect minor brain damage. [9] There are only few studies thus far to have used GOS to predict the outcome of AE. Although no specific scale has been designed yet to predict AE prognosis, [10] some studies have supported the use of the modified Rankin Scale (mRS), which is more frequently used in the evaluation of AE prognosis. [11][12][13][14] Another scale called the Response to Immunotherapy in Epilepsy and Encephalopathy score (RITE2 score) has also been used to evaluate and manage autoimmune-epilepsy. [15,16] In summary, this is a meaningful report providing epidemiological data about the antibody distribution in AE in the Chongqing area, along with revealing the factors associated with poor prognosis of AE. Despite some of the abovementioned concerns, this study would be helpful to researchers and clinicians alike to gain more insight into AE.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: